KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
[Cisplatin promotes PD-L1 expression in A549 human lung adenocarcinoma cells via activating the ERK pathway]. PMID 34670665 · Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi · 2021-Oct The study is a preclinical in vitro investigation of cisplatin's effect on PD-L1 expression in a lung cancer cell line. It is randomized but not a clinical trial, lacks a defined clinical trial phase, and does not measure any time-to-event clinical efficacy endpoint. It is therefore excluded.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial. PMID 34592178 · Lancet Oncol · 2021-Oct The record describes a study design for multi-cancer screening blood tests, focusing on early detection and mortality outcomes. It is a randomized trial design in humans with oncology relevance, but it is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention. The abstract does not indicate a time-to-event efficacy endpoint (e.g., OS, PFS) or Kaplan-Meier/HR results; it is a design/methodology article, not a report of trial results. Therefore, it does not meet key eligibility criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. PMID 34543864 · ESMO Open · 2021-Oct The record describes the safety run-in results from the FLAURA2 study. While it is from a Phase III randomized trial with a drug intervention, the reported results are purely safety and tolerability data, not the primary or key secondary time-to-event efficacy endpoints (e.g., OS, PFS, DFS, etc.) required for inclusion.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial. PMID 34254530 · Future Oncol · 2021-Oct The record describes the trial design and a biomarker-based treatment adaptation strategy for a Phase III randomized trial in FLT3-mutated AML. It does not report any formal efficacy results (e.g., survival, response rates) or time-to-event data. It is a protocol/methodology description, not a results report.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study. PMID 34229554 · Curr Med Res Opin · 2021-Oct The report is an original secondary/biomarker analysis from a randomized trial with drug intervention and time-to-event endpoints, but it is not the primary efficacy report of the trial. The trial phase is not explicitly established in the provided metadata (e.g., publication types or abstract text), which is required for eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prospective assessment of diagnostic efficacy and safety of SonazoidTM and SonoVue® ultrasound contrast agents in patients with focal liver lesions. PMID 34136936 · Abdom Radiol (NY) · 2021-Oct The study is a prospective Phase 3 trial assessing diagnostic accuracy of ultrasound contrast agents for liver lesions, not a randomized therapeutic trial. It lacks a drug intervention for treatment and a time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Extraskeletal Ewing sarcoma in children, adolescents, and young adults. An analysis of three prospective studies of the Cooperative Weichteilsarkomstudiengruppe (CWS). PMID 34089219 · Pediatr Blood Cancer · 2021-Oct The record reports results from three prospective pediatric oncology studies (CWS-91, CWS-96, CWS-2002P) for extraskeletal Ewing sarcoma, with one randomized comparison (CWS-96) and primary time-to-event endpoints (EFS, OS). However, the formal trial phase (e.g., Phase III/IIIb or Phase II/III) is not explicitly stated in the title, abstract, or metadata. Without clear evidence of the trial phase, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. PMID 34031532 · Leukemia · 2021-Oct Title indicates a Phase III trial in multiple myeloma with a drug intervention (bortezomib), but lacks explicit signals for a time-to-event efficacy endpoint, randomization, or original result status. Without the abstract or full text, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effectiveness of management of severe acute malnutrition (SAM) through community health workers as compared to a traditional facility-based model: a cluster randomized controlled trial. PMID 33880645 · Eur J Nutr · 2021-Oct The study is a cluster randomized trial for severe acute malnutrition, not a human malignant-neoplasm trial. It lacks a time-to-event efficacy endpoint (OS, PFS, etc.) and a drug-containing intervention (the intervention is a community health worker model, not a drug).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[Chronic radiation-induced rectal injury after adjuvant radiotherapy for pelvic malignant tumors: report based on a phase 3 randomized clinical trial]. PMID 34823296 · Zhonghua Wei Chang Wai Ke Za Zhi · 2021-Nov-25 The record describes a retrospective observational study analyzing the incidence of chronic radiation-induced rectal injury and quality of life in patients from a Phase III randomized trial. While it originates from a randomized Phase III trial with drug interventions (cisplatin, paclitaxel), the reported analysis does not include a time-to-event efficacy endpoint (e.g., overall survival, progression-free survival) as the primary or key secondary outcome. The outcomes analyzed are safety/toxicity (chronic radiation injury) and patient-reported quality of life. Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort requiring a primary/key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. PMID 34407542 · Blood · 2021-Nov-25 The study is a Phase 3 randomized trial with a drug intervention, but the primary endpoint is a categorical response rate (major molecular response at week 24), not a time-to-event endpoint. No time-to-event outcomes are reported in the abstract.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The Impact of Radiation Therapy in Children and Adolescents With Metastatic Rhabdomyosarcoma. PMID 34217789 · Int J Radiat Oncol Biol Phys · 2021-Nov-15 This is a retrospective secondary analysis of a randomized trial, evaluating the impact of radiation therapy, not the primary drug comparison. The original trial was randomized and involved a drug (bevacizumab), but this report does not present the primary, definitive Phase III/IIIb results for the drug intervention.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804. PMID 34406870 · J Clin Oncol · 2021-Nov-10 This is an eligible Phase III randomized oncology trial with a time-to-event primary endpoint, but it lacks a drug-containing intervention as the primary studied treatment. The trial compares radiation therapy (a non-drug intervention) versus observation, with tamoxifen use being optional and not the primary intervention being evaluated.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma. PMID 34388007 · J Clin Oncol · 2021-Nov-10 The study is a randomized trial in oncology with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Its reported outcomes are predicted cardiovascular risks, which are a safety/toxicity analysis, not a time-to-event efficacy analysis. Therefore, it does not meet the eligibility criteria for the KM digitization cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. PMID 34740331 · BMC Cancer · 2021-Nov-05 This is a protocol for a randomized Phase II/III trial. It does not report results; it only describes the trial design. The abstract does not mention a drug-containing intervention (it compares NGS-guided strategy vs. standard care, not a specific drug regimen). It also does not explicitly report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR data.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. PMID 34529000 · JAMA Oncol · 2021-Nov-01 The record is for a randomized clinical trial in oncology with a drug intervention and a time-to-event primary/secondary endpoint. However, the explicit phase (Phase III/IIIb or II/III) is not established in the provided metadata (title, abstract, publication types). The abstract describes a platform trial (I-SPY2) where investigational agents are compared to chemotherapy in a 1:1 randomized setting, but it does not explicitly state the trial is Phase III/IIIb or Phase II/III. The 'phase3_or_definitive' criterion cannot be confirmed, so eligibility is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Financial relationships between industry and principal investigators of US cooperative group randomized cancer clinical trials. PMID 34173669 · Int J Cancer · 2021-Nov-01 This is an observational study analyzing financial conflicts of interest among principal investigators of cooperative group trials, not a report of a randomized clinical trial's efficacy results. It does not present any original time-to-event data or Kaplan-Meier analysis for a drug intervention.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: Interim analysis of the PRECAVE randomized clinical trial. PMID 34726625 · Arch Esp Urol · 2021-Nov The record is an interim analysis of a randomized trial for an oncology drug intervention with a time-to-event endpoint. However, the required definitive phase (III/IIIb or II/III) cannot be explicitly established from the provided metadata. The deterministic review flags 'phase3_evidence_unclear', and the abstract does not specify the trial phase. Therefore, it does not meet all criteria for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors. PMID 34672682 · Future Oncol · 2021-Nov This is a review article summarizing multiple studies presented at a conference, not an original report of a single trial. While it mentions Phase III randomized trials, it does not provide specific time-to-event efficacy data or a clear drug intervention for a specific trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Trastuzumab Deruxtecan Data Impresses at ESMO. PMID 34548307 · Cancer Discov · 2021-Nov The record is a news item summarizing a trial, not the original primary research article. The abstract does not explicitly state a specific time-to-event efficacy endpoint or provide Kaplan-Meier or HR data, preventing eligibility confirmation.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. PMID 34543941 · Lung Cancer · 2021-Nov The record is an original, pooled analysis of two randomized trials with a drug intervention and time-to-event efficacy endpoints (OS, PFS). However, the phase of the constituent trials is not explicitly confirmed in the provided metadata or abstract as Phase III/IIIb or Phase II/III. The deterministic review flagged 'phase3_evidence_unclear'. Therefore, the phase criterion cannot be definitively established from the given information.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial. PMID 34368999 · Clin Endocrinol (Oxf) · 2021-Nov The study is a randomized trial in oncology with a drug intervention, but it lacks a primary time-to-event efficacy endpoint as defined by the criteria (OS, PFS, DFS, etc., with KM or HR). The outcomes are categorical response rates at a final follow-up, not time-to-event data.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma. PMID 34269067 · Future Oncol · 2021-Nov The provided text is a protocol or study design description for a Phase III trial, not an original result report. It establishes oncology, human, randomization, phase, and drug intervention, but does not report any efficacy results or time-to-event endpoints.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer. PMID 34184929 · J Urol · 2021-Nov The study is a secondary/prognostic analysis of biomarker (testosterone) data from the continuous ADT arm of a randomized trial. It does not report a primary drug intervention efficacy comparison (e.g., drug A vs drug B). The drug intervention criterion is not met.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Debating Pros and Cons of Total Neoadjuvant Therapy in Rectal Cancer. PMID 34944980 · Cancers (Basel) · 2021-Dec-18 The record is not an original formal-result report of a randomized trial; it is a commentary/editorial discussing the pros and cons of total neoadjuvant therapy based on other trials. Furthermore, it does not contain explicit time-to-event efficacy endpoint data (e.g., OS, PFS, DFS with Kaplan-Meier curves or HR). Therefore, it does not meet the criteria for inclusion.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The Efficacy of Preoperative Duloxetine in Patients Undergoing Major Abdominal Cancer Surgery: A Randomized Controlled Trial. PMID 34757343 · Clin J Pain · 2021-Dec-01 The study is a randomized, placebo-controlled trial in patients undergoing cancer surgery, evaluating the analgesic and recovery benefits of preoperative duloxetine. However, it is not a trial of a cancer treatment drug (it's an analgesic adjunct), the trial phase is not specified (no evidence of Phase III/IIIb), and the primary endpoints are postoperative pain, morphine consumption, and quality of recovery, none of which are time-to-event efficacy endpoints (OS, PFS, DFS, etc.) typically required for Kaplan-Meier analysis in oncology drug trials. The intervention is not a systemic cancer therapy, and the study does not report survival or progression-free outcomes.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study. PMID 31855875 · Ann Surg · 2021-Dec-01 The record describes a randomized, human, oncology trial with a drug-containing intervention and primary time-to-event endpoints (OS, DFS). However, the phase of the trial is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types, MeSH). The deterministic review signal 'phase3_evidence_unclear' correctly notes this ambiguity. Without confirmation of a definitive phase, eligibility cannot be established with certainty.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias. PMID 34673442 · Leuk Res · 2021-Dec The study is a secondary analysis of a phase I/II trial evaluating bosutinib dose reduction effects in Ph+ leukemias. While it meets criteria for oncology, human, drug intervention, and phase (with phase III listed in publication types but not definitively as the primary study design), it lacks a time-to-event primary or key secondary endpoint. The efficacy endpoint is cytogenetic response, not a survival or progression endpoint. The report is not a primary result of a randomized phase III trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin. PMID 34554372 · Breast Cancer Res Treat · 2021-Dec The record describes a randomized trial in oncology (breast cancer) with a drug intervention (aromatase inhibitors), but the abstract reports results on biomarker (leptin) changes, not a time-to-event efficacy endpoint. The trial phase is not specified in the provided information, preventing confirmation of Phase III/IIIb or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Procalcitonin kinetics to guide sequential invasive-noninvasive mechanical ventilation weaning in patients with acute exacerbation of chronic obstructive pulmonary disease and respiratory failure: procalcitonin's adjunct role. PMID 34357857 · Libyan J Med · 2021-Dec The study is a randomized trial in a human non-oncology population (COPD exacerbation) comparing procalcitonin-guided weaning to a control method. There is no drug-containing intervention; the intervention is diagnostic/timing-based. The primary endpoints are clinical outcomes (inflammation markers, ventilation duration, complications, costs, mortality), not time-to-event efficacy endpoints like OS or PFS. Phase is not specified as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Correction to: Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial. PMID 33839979 · Ann Surg Oncol · 2021-Dec This is a published erratum for a Phase III trial in HCC with a drug intervention. However, the abstract and metadata provide no explicit signal for a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The deterministic review also flagged a lack of time-to-event signal. As an erratum, it is not an original formal result report of the trial's efficacy.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging. PMID 34417899 · EJNMMI Res · 2021-Aug-21 The record is a secondary analysis of imaging data from a Phase III trial, not the primary efficacy report for a drug intervention.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. PMID 33951180 · Cancer · 2021-Aug-15 The study is oncologic, human, includes a drug intervention, and reports original results for time-to-event endpoints. However, the abstract does not explicitly state the trial phase (e.g., Phase III, Phase II/III) or randomization status, which are required criteria for definitive eligibility. Therefore, is_eligible is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[The role of neoadjuvant therapy in multimodality treatment of locally advanced esophageal squamous cell carcinoma: perspective from the NEOCRTEC5010 trial]. PMID 34192855 · Zhonghua Wai Ke Za Zhi · 2021-Aug-01 This is a review article summarizing and discussing the NEOCRTEC5010 trial, not the original trial report presenting primary efficacy results with time-to-event endpoints.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice. PMID 34377934 · JNCI Cancer Spectr · 2021-Aug The record describes a retrospective biomarker analysis (MAF amplification) of a randomized trial (NSABP B-34), making it a subgroup or secondary analysis. The phase of the underlying trial is not explicitly stated in the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases. PMID 34333237 · EBioMedicine · 2021-Aug The record describes a biomarker analysis within a Phase III randomized trial for colorectal cancer, with a clear time-to-event endpoint (RFS). However, the specific drug intervention(s) being compared in the parent trial are not stated in the provided abstract. The report itself is a secondary/prognostic analysis of ctDNA, not a primary efficacy report of a drug. Eligibility cannot be established without explicit evidence of a drug-containing intervention in the analyzed comparison.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[Not Available]. PMID 34318458 · Aktuelle Urol · 2021-Aug The record's publication types and MeSH terms establish oncology, human, randomized, Phase III, and drug intervention criteria. However, the empty abstract prevents verification of a primary/key time-to-event efficacy endpoint, which is a required criterion for eligibility.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. PMID 34312547 · Nat Immunol · 2021-Aug The record lacks explicit evidence of a randomized trial with a drug intervention and a time-to-event efficacy endpoint. The abstract describes an immunology/epigenetics study, not a clinical trial efficacy result. The 'Clinical Trial, Phase III' publication type is likely erroneous or incidental, as the content does not match the required trial report structure.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. PMID 34272041 · Ann Oncol · 2021-Aug The record describes a randomized, placebo-controlled trial in metastatic triple-negative breast cancer with overall survival as a primary endpoint, reporting final results. However, the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata; it is inferred from the trial design and scope. Since the phase cannot be definitively established from the text alone, eligibility is set to null pending verification of the official trial phase.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. PMID 34037282 · Oncologist · 2021-Aug The report is an original result from a randomized trial with drug intervention and time-to-event endpoints, but it is explicitly a prognostic subgroup analysis within the PALOMA-3 trial. Phase III/IIIb or Phase II/III status is not explicitly established in the provided metadata or abstract text.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. PMID 33932503 · Ann Oncol · 2021-Aug The record is eligible because it is a secondary analysis (subgroup/safety) from an original, definitive Phase III randomized trial with a primary time-to-event efficacy endpoint (IDFS) and a drug-containing intervention. The trial phase is confirmed by the study being a large, randomized trial with a primary efficacy endpoint in oncology, which is characteristic of Phase III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade. PMID 33728733 · Oncologist · 2021-Aug This is a retrospective analysis of publication bias and accrual in gastrointestinal oncology trials, not a report of an individual randomized trial's clinical efficacy results. It does not present time-to-event data (e.g., OS, PFS) or report on a drug intervention's effect. Therefore, it does not meet the inclusion criteria for a trial result report.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma : First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial. PMID 33226469 · Strahlenther Onkol · 2021-Aug The record describes a quality control study of radiotherapy within a Phase II/III trial. While it is oncologic and in humans, it lacks evidence of a randomized comparison, a drug intervention, and a time-to-event efficacy endpoint (e.g., OS, PFS, KM, HR). The focus is on technical deviations, not treatment efficacy.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
PMID 42485480 PMID 42485480 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42485474 PMID 42485474 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42485473 PMID 42485473 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42479860 PMID 42479860 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42341142 PMID 42341142 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
B
仅广召回影子组 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42330139 PMID 42330139 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42190031 PMID 42190031 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -